Nouvelle étape du consortium SNC : découvrez INSPiRE

« Neuron Experts, Motac Neuroscience, and Cynbiose are proud to officially unveil the name of their strategic partnership: INSPiRE.

In a world where the population is getting older, the burden of neurodegenerative diseases is growing rapidly and is affecting families and healthcare systems worldwide. According to a recent study, Parkinson’s disease is projected to affect over 25.2 million people by 2050, while Alzheimer’s disease cases are expected to reach 80 million by 2040 globally (BMJ, 2025).

INSPiRE embodies a new stage reflecting the shared ambition of three leading preclinical CROs to accelerate research in neurology by offering a translational joint expertise to support CNS drug development. Our partnership is an end-to-end solution combining the in vitro expertise for the neurodegenerative model of Neuron Experts, the in vivo neurological disease models of Motac Neuroscience, and Cynbiose’s expertise in efficacy and toxicity studies in non-human primate models.

Motac Neuroscience brings to INSPiRE its long-standing expertise in translational neuroscience, built on advanced in vivo models of Parkinson’s and Alzheimer’s disease. By combining behavioural, histological, and neurochemical endpoints within these models, Motac contributes to refining and reinforcing the consortium’s preclinical evaluation capabilities.

Working hand in hand with Motac, Neuron Experts’ advanced in vitro systems reveal the earliest cellular mechanisms of neurodegeneration and provide a mechanistic framework to Motac’s in vivo models. This offer is completed by Cynbiose’s ability to run IND-enabling toxicology and CNS-targeting biodistribution studies in NHP, leveraging state-of-the-art neurosurgical and imaging capabilities.

This integrated approach is central to INSPiRE’s ambition to deliver more predictive and clinically relevant preclinical data.